XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

XLV, a broad healthcare ETF, offers lower costs (0.08% expense ratio) and higher dividend yield (1.60%) with more stability, while IBBQ, a concentrated biotech ETF, delivered stronger one-year returns (45.52% vs 26.79%) but with significantly higher volatility and drawdown risk. The choice depends on investor risk tolerance and investment objectives.

08/01/2026, 5:11 PM • The Motley Fool

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees

Vanguard Health Care ETF (VHT) outperforms VanEck Biotech ETF (BBH) with lower fees (0.09% vs 0.35%), higher dividend yield (1.6% vs 0.5%), and superior 5-year returns ($1,278 vs $1,004 on $1,000 invested). VHT offers broad diversification across 411 healthcare holdings, while BBH provides concentrated biotech exposure with 25 stocks and higher volatility.

07/28/2026, 8:20 AM • The Motley Fool

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) with 110 holdings offering global diversification and lower volatility, versus VanEck Biotech ETF (BBH) with 25 concentrated biotech positions delivering higher short-term returns but greater drawdown risk. IXJ is recommended for its superior long-term performance, geographic diversity, and stability despite BBH's impressive 30.8% one-year return.

07/23/2026, 3:30 PM • The Motley Fool

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

Cathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.

07/22/2026, 5:30 AM • The Motley Fool

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

07/17/2026, 6:48 AM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.

07/12/2026, 3:30 PM • The Motley Fool

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

Gilead Sciences is expanding beyond its core HIV business with four potential drug launches in 2026, including treatments for hepatitis delta virus, multiple myeloma, and breast cancer. Despite strong financials (Q1 revenue up 4% YoY, EPS up 54.8%), the stock has only risen 9% this year. The company's strategic acquisitions and diversified pipeline, combined with no major patent cliffs until 2036 and an attractive 2.39% dividend yield, suggest investors are undervaluing the company's growth potential.

07/12/2026, 9:23 AM • The Motley Fool

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

07/08/2026, 7:28 AM • The Motley Fool

BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients

BBG Advanced Therapies, a subsidiary of BioBridge Global, has partnered with Kite (a Gilead Company) to deploy a Mobile Leukapheresis Center across Texas. This first-of-its-kind platform brings T-cell collection directly to patients' communities, reducing travel burdens and expanding access to Kite's CAR T-cell therapies for blood cancer treatment. The initiative addresses the gap where only 2 in 10 eligible U.S. patients currently receive these treatments.

07/07/2026, 10:00 AM • GlobeNewswire

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

Gilead Sciences and Merck discontinued their Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy plus Keytruda for lung cancer after the combination failed to reach statistical significance in progression-free survival with low probability of overall survival benefit. However, the companies reported positive Phase 3 results for an investigational once-weekly oral HIV regimen combining islatravir and lenacapavir, which met its primary efficacy endpoints in two studies.

06/09/2026, 1:44 PM • Benzinga

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome

Gilead Sciences announced positive Phase 3 IDEAL study results for Livdelzi (seladelpar) in treating primary biliary cholangitis (PBC). The drug significantly improved alkaline phosphatase (ALP) normalization compared to placebo in patients with inadequately controlled disease. The company plans to present full data at a medical congress and engage with regulatory authorities. However, GILD shares fell 2.01% on the news.

06/02/2026, 1:47 PM • Benzinga

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More

RTW Investments, a biotech-focused fund, purchased 11.8 million shares of Tango Therapeutics for approximately $164.37 million in Q1 2026, increasing its stake to roughly 3% of AUM. The purchase comes as TNGX stock has surged 840% over the past year. The investment reflects confidence in Tango's lead candidate vopimetostat and upcoming clinical data for MTAP-deleted cancers, with the company well-funded through 2028.

05/29/2026, 8:21 PM • The Motley Fool

Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases

Oorja Bio, a new clinical-stage biopharmaceutical company, announced a $30 million Series A funding round from Westlake BioPartners to develop ORJ-001, a first-in-class peptide therapeutic for idiopathic pulmonary fibrosis (IPF). The company has received FDA IND clearance and plans to initiate Phase 2 clinical trials in 2026. ORJ-001 is designed to restore alveolar epithelial type 2 (AEC2) cell function to promote lung repair and reverse fibrosis, addressing a significant unmet medical need in IPF treatment.

05/19/2026, 3:00 PM • GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including BTK degraders and CBL-B inhibitors, alongside partnerships with Sanofi, Gilead, and Pfizer.

05/13/2026, 7:00 AM • GlobeNewswire